Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some
patients with HCC initially respond to sorafenib, but eventually succumb to the disease …

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

Background Intrahepatic cholangiocarcinoma (ICC) is rising in clinical importance due to the
increasing incidence worldwide, poor prognosis, and suboptimal response to therapies …

Purpose Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-
proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib
prolongs survival of patients with advanced disease and is approved for the systemic …

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second
largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent …

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …